PMX-53

PMX-53 is a dual-activity compound functioning as a Mas-related G-protein coupled receptor X2 (MrgX2) agonist and a complement C5a receptor (C5aR/CD88) antagonist. Research demonstrates its efficacy in reducing atherosclerotic lesions in mice, inhibiting breast cancer lung metastasis, and attenuating C5a-induced hypernociception in rat models.